Patents by Inventor Marion PÖNISCH
Marion PÖNISCH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230332163Abstract: The present invention relates to the field of biomedicine, and in particular to the field of therapeutic nucleic acids. The present invention provides artificial nucleic acids, in particular RNAs, encoding CRISPR-associated proteins. A (pharmaceutical) composition and kit-of-parts comprising the same are also provided. Furthermore, the present invention relates to the artificial nucleic acid, (pharmaceutical) composition, or kit-of-parts for use in medicine, and in particular in the treatment and/or prophylaxis of diseases amenable to treatment with CRISPR-associated proteins.Type: ApplicationFiled: July 3, 2023Publication date: October 19, 2023Applicant: CureVac SEInventors: Frédéric CHEVESSIER-TÜNNESEN, Marion POENISCH, Thomas SCHLAKE
-
Patent number: 11739335Abstract: The present invention relates to the field of biomedicine, and in particular to the field of therapeutic nucleic acids. The present invention provides artificial nucleic acids, in particular RNAs, encoding CRISPR-associated proteins. A (pharmaceutical) composition and kit-of-parts comprising the same are also provided. Furthermore, the present invention relates to the artificial nucleic acid, (pharmaceutical) composition, or kit-of-parts for use in medicine, and in particular in the treatment and/or prophylaxis of diseases amenable to treatment with CRISPR-associated proteins.Type: GrantFiled: March 23, 2018Date of Patent: August 29, 2023Assignee: CureVac SEInventors: Frédéric Chevessier-Tünnesen, Marion Poenisch, Thomas Schlake
-
Publication number: 20230183670Abstract: The present invention relates to an RNA encoding a therapeutic protein, in particular a collagenase, growth factor, cytokine, receptor, chaperone or signal transduction inhibitor. In particular, the present invention relates to RNA suitable for treatment of wounds, specifically for promoting wound healing. The present invention concerns such RNA as well as pharmaceutical compositions and kits and combinations comprising the RNA. Furthermore, the present invention relates to the RNA, pharmaceutical compositions, kits as disclosed herein for use in the treatment of wounds, specifically for promoting wound healing.Type: ApplicationFiled: November 17, 2022Publication date: June 15, 2023Applicant: CureVac SEInventors: Nigel HORSCROFT, Marion PÖNISCH, Christine WEINL-TENBRUCK
-
Publication number: 20230158126Abstract: The present invention relates to an RNA suitable for treatment or prophylaxis of liver diseases. In particular, the present invention provides an RNA encoding at least one peptide or protein selected from the group consisting of an extracellular matrix protease, CCAAT/enhancer-binding protein alpha (CEBPA), TNF-related apoptosis-inducing ligand (TRAIL), Hepatocyte Growth Factor (HGF), hepatocyte nuclear factor 4 alpha (HNF4A), fibroblast growth factor 21 (FGF21), opioid growth factor receptor-like 1 (OGFRL1), Relaxin 1 (RLN1), Relaxin 2 (RLN2) and Relaxin 3 (RLN3), or a fragment or a variant of any of these peptides or proteins. The present invention concerns said RNA as well as compositions and kits comprising the RNA. Furthermore, the present invention relates to the RNA, compositions or kits as disclosed herein for use as a medicament, in particular for treatment or prophylaxis of a liver disease.Type: ApplicationFiled: September 6, 2022Publication date: May 25, 2023Applicant: CureVac SEInventors: Nigel HORSCROFT, Marion PÖNISCH, Christine WEINL-TENBRUCK, Frédéric CHEVESSIER-TÜNNESEN
-
Patent number: 11542490Abstract: The present invention relates to an RNA encoding a therapeutic protein, in particular a collagenase, growth factor, cytokine, receptor, chaperone or signal transduction inhibitor. In particular, the present invention relates to RNA suitable for treatment of wounds, specifically for promoting wound healing. The present invention concerns such RNA as well as pharmaceutical compositions and kits and combinations comprising the RNA. Furthermore, the present invention relates to the RNA, pharmaceutical compositions, kits as disclosed herein for use in the treatment of wounds, specifically for promoting wound healing.Type: GrantFiled: December 8, 2017Date of Patent: January 3, 2023Assignee: CureVac SEInventors: Nigel Horscroft, Marion Pönisch, Christine Weinl-Tenbruck
-
Patent number: 11464836Abstract: The present invention relates to an RNA suitable for treatment or prophylaxis of liver diseases. In particular, the present invention provides an RNA encoding at least one peptide or protein selected from the group consisting of an extracellular matrix protease, CCAAT/enhancer-binding protein alpha (CEBPA), TNF-related apoptosis-inducing ligand (TRAIL), Hepatocyte Growth Factor (HGF), hepatocyte nuclear factor 4 alpha (HNF4A), fibroblast growth factor 21 (FGF21), opioid growth factor receptor-like 1 (OGFRL1), Relaxin 1 (RLN1), Relaxin 2 (RLN2) and Relaxin 3 (RLN3), or a fragment or a variant of any of these peptides or proteins. The present invention concerns said RNA as well as compositions and kits comprising the RNA. Furthermore, the present invention relates to the RNA, compositions or kits as disclosed herein for use as a medicament, in particular for treatment or prophylaxis of a liver disease.Type: GrantFiled: December 8, 2017Date of Patent: October 11, 2022Assignee: CureVac AGInventors: Nigel Horscroft, Marion Pönisch, Christine Weinl-Tenbruck, Frédéric Chevessier-Tünnesen
-
Publication number: 20220233568Abstract: The present invention provides artificial nucleic acid molecules comprising novel combinations of 5? and 3? untranslated region (UTR) elements. The inventive nucleic acid molecules are preferably characterized by increased expression efficacies of coding regions operably linked to said UTR elements. The artificial nucleic acids can be used for treatment or prophylaxis of various diseases. The invention further provides (pharmaceutical) compositions, vaccines and kits comprising said artificial nucleic acid molecules. Further, in vitro methods for preparing artificial nucleic acid molecules according to the invention are provided.Type: ApplicationFiled: October 17, 2018Publication date: July 28, 2022Inventors: Thomas SCHLAKE, Andreas THESS, Moritz THRAN, Frédéric CHEVESSIER-TÜNNESEN, Marion PÖNISCH
-
Publication number: 20210403925Abstract: The present invention relates to the field of biomedicine, and in particular to the field of therapeutic nucleic acids. The present invention provides artificial nucleic acids, in particular RNAs, encoding CRISPR-associated proteins. A (pharmaceutical) composition and kit-of-parts comprising the same are also provided. Furthermore, the present invention relates to the artificial nucleic acid, (pharmaceutical) composition, or kit-of-parts for use in medicine, and in particular in the treatment and/or prophylaxis of diseases amenable to treatment with CRISPR-associated proteins.Type: ApplicationFiled: March 23, 2018Publication date: December 30, 2021Inventors: Frédéric CHEVESSIER-TÜNNESEN, Marion POENISCH, Thomas SCHLAKE
-
Publication number: 20200149026Abstract: The present invention relates to an RNA encoding a therapeutic protein, in particular a collagenase, growth factor, cytokine, receptor, chaperone or signal transduction inhibitor. In particular, the present invention relates to RNA suitable for treatment of wounds, specifically for promoting wound healing. The present invention concerns such RNA as well as pharmaceutical compositions and kits and combinations comprising the RNA. Furthermore, the present invention relates to the RNA, pharmaceutical compositions, kits as disclosed herein for use in the treatment of wounds, specifically for promoting wound healing.Type: ApplicationFiled: December 8, 2017Publication date: May 14, 2020Inventors: Nigel HORSCROFT, Marion PÖNISCH, Christine WEINL
-
Publication number: 20190343933Abstract: The present invention relates to an RNA suitable for treatment or prophylaxis of liver diseases. In particular, the present invention provides an RNA encoding at least one peptide or protein selected from the group consisting of an extracellular matrix protease, CCAAT/enhancer-binding protein alpha (CEBPA), TNF-related apoptosis-inducing ligand (TRAIL), Hepatocyte Growth Factor (HGF), hepatocyte nuclear factor 4 alpha (HNF4A), fibroblast growth factor 21 (FGF21), opioid growth factor receptor-like 1 (OGFRL1), Relaxin 1 (RLN1), Relaxin 2 (RLN2) and Relaxin 3 (RLN3), or a fragment or a variant of any of these peptides or proteins. The present invention concerns said RNA as well as compositions and kits comprising the RNA. Furthermore, the present invention relates to the RNA, compositions or kits as disclosed herein for use as a medicament, in particular for treatment or prophylaxis of a liver disease.Type: ApplicationFiled: December 8, 2017Publication date: November 14, 2019Inventors: Nigel HORSCROFT, Marion PÖNISCH, Christine WEINL-TENBRUCK